The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Trial Profile

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms ATTAIN
  • Most Recent Events

    • 18 Aug 2017 Status changed from active, no longer recruiting to discontinued due to poor accrual.
    • 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 02 Jul 2015 Planned primary completion date changed from 1 Aug 2019 to 1 Jul 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top